- F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
- The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
- FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
- In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
- F-Star ended the quarter with cash and cash equivalents of $81.6 million.
- Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.
Wells Fargo Maintains Equal-Weight on Autoliv, Raises Price Target to $80
Wells Fargo analyst Colin Langan maintains Autoliv (NYSE:ALV) with a Equal-Weight and raises the price target from $74 to $80.
